Hyperprogression: A novel response pattern under immunotherapy

Hyperprogression: A novel response pattern under immunotherapy

Abstract Checkpoint blockade therapy has shown significant therapeutic benefits and resulted in durable responses in patients with various tumors. However, accumulating evidence has demonstrated that 4‐29% of all patients with cancers with various histologies may suffer from tumor flare following su...

Full description

Bibliographic Details
Main Authors:	Xue‐jiao Han, Aqu Alu, Yi‐nan Xiao, Yu‐quan Wei, Xia‐wei Wei
Format:	Article
Language:	English
Published:	Wiley 2020-09-01
Series:	Clinical and Translational Medicine
Subjects:	checkpoint blockade therapy HPD hyperprogression hyperprogressive disease PD‐1/PD‐L1
Online Access:	https://doi.org/10.1002/ctm2.167

Similar Items

Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
by: Hasan Cagri Yildirim, et al.
Published: (2022-09-01)

Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence
by: Jianpei Zheng, et al.
Published: (2023-02-01)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
by: Marjorie Faure, et al.
Published: (2018-04-01)

IFN-γ and CD38 in Hyperprogressive Cancer Development
by: Stefania Angelicola, et al.
Published: (2021-01-01)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
by: Zhanqi Wei, et al.
Published: (2022-05-01)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
by: Serena Indino, et al.
Published: (2022-12-01)

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
by: R. Riera-Sala, et al.
Published: (2023-09-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
by: Yao Zhang, et al.
Published: (2024-12-01)

Advances in Hyperprogressive Disease in Patients  with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy
by: Shuyang YAO, et al.
Published: (2021-04-01)

Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
by: Changshun Wu, et al.
Published: (2022-12-01)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
by: Hongjing Zang, et al.
Published: (2020-04-01)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
by: Erich Sabio, et al.
Published: (2019-07-01)

Hyperprogressive Disease: Main Features and Key Controversies
by: Hugo Arasanz, et al.
Published: (2021-04-01)

Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
by: Mikolaj Kocikowski, et al.
Published: (2020-03-01)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
by: Hugo Arasanz, et al.
Published: (2020-02-01)

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
by: Kosuke Masuda, et al.
Published: (2023-11-01)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
by: Xiaojun Liu, et al.
Published: (2022-03-01)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
by: H. S. Gabryś, et al.
Published: (2022-11-01)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
by: Rishu Singla, et al.
Published: (2021-04-01)

Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease
by: Lixia Xia, et al.
Published: (2021-12-01)

Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
by: Li-ping Zhao, et al.
Published: (2022-06-01)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
by: Simone Camelliti, et al.
Published: (2020-11-01)

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy
by: Lu Zhang, et al.
Published: (2021-01-01)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01)

Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
by: Jan Skacel, et al.
Published: (2023-12-01)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
by: Morgane Denis, et al.
Published: (2020-03-01)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
by: Jehun Kim, et al.
Published: (2022-08-01)

Is there an association between lymph node size and hyperprogression in immunotherapy-treated patients?
by: Alkader Mohammad S., et al.
Published: (2024-03-01)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
by: Whitney Barham, et al.
Published: (2021-02-01)

Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma
by: Lei Wu, et al.
Published: (2020-09-01)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
by: Rui Zhou, et al.
Published: (2023-11-01)

A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice
by: Guo Hanfei, et al.
Published: (2021-12-01)

A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation
by: Tomoyo Oguri, et al.
Published: (2021-01-01)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
by: Alec S. Britt, et al.
Published: (2022-11-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01)

Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
by: Shuyue Wang, et al.
Published: (2021-07-01)